+468.1%
HUT vs GSK
+58.9%
+409.2%
-65.5%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 3y.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | +1.4% | -2.3% | +3.7% | +0.4% |
| 7D | -4.9% | -3.0% | -1.9% | -6.1% |
| 30D | -20.3% | +0.4% | -20.7% | -19.4% |
| 3M | -38.7% | -1.2% | -37.5% | -37.9% |
| 6M | -47.3% | +0.9% | -48.3% | -46.1% |
| YTD | +17.5% | +4.0% | +13.5% | +23.4% |
| 1Y | +43.2% | +7.3% | +35.9% | +52.2% |
| 3Y | +468.1% | +57.1% | +411.0% | +512.2% |
| All | +468.1% | +58.9% | +409.2% | +512.2% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 3y: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
3y analysis · Full analysis span regression · 6 months rolling